229 related articles for article (PubMed ID: 35831714)
1. Preclinical and first-in-human evaluation of
Zhou M; Wang X; Chen B; Xiang S; Rao W; Zhang Z; Liu H; Fang J; Yin X; Deng P; Zhang X; Hu S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4312-4324. PubMed ID: 35831714
[TBL] [Abstract][Full Text] [Related]
2. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation and pilot clinical study of [
Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
[TBL] [Abstract][Full Text] [Related]
4. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
[No Abstract] [Full Text] [Related]
5. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
[TBL] [Abstract][Full Text] [Related]
6. Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer.
Chen L; Fu H; He H; Lou K; Li Q; Ye J; Feng G; Yu C
Mol Pharm; 2023 Aug; 20(8):4277-4284. PubMed ID: 37463487
[TBL] [Abstract][Full Text] [Related]
7. [
Zhou M; Xiang S; Zhao Y; Tang Y; Yang J; Yin X; Tian J; Hu S; Du Y
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):369-379. PubMed ID: 37759096
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Imaging of the Programmed Death Ligand 1 by
González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
[TBL] [Abstract][Full Text] [Related]
9. Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer
Stutvoet TS; van der Veen EL; Kol A; Antunes IF; de Vries EFJ; Hospers GAP; de Vries EGE; de Jong S; Lub-de Hooge MN
J Nucl Med; 2020 Dec; 61(12):1839-1844. PubMed ID: 32358092
[No Abstract] [Full Text] [Related]
10. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Biologic Evaluation of a Novel
Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of Al[
Sun P; Han Y; Hu K; Huang S; Wang M; Zhou K; Fu L; Chen H; Tang G
Bioorg Chem; 2022 May; 122():105682. PubMed ID: 35278777
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
[TBL] [Abstract][Full Text] [Related]
14. A Novel Small Cyclic Peptide-Based
Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492
[TBL] [Abstract][Full Text] [Related]
15. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
16. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
[TBL] [Abstract][Full Text] [Related]
17. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer.
Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ
Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Evaluation of [
Huang J; Bai L; Shi D; Jiang W; Chen P; Dong Y; Zhang X; Peng J; Hou J; Lu Y; Huang X; Tang G; Huang S
Mol Pharm; 2024 May; 21(5):2425-2434. PubMed ID: 38554143
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and exploratory human studies of novel
Wang X; Zhou M; Chen B; Liu H; Fang J; Xiang S; Hu S; Zhang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2584-2594. PubMed ID: 35037984
[TBL] [Abstract][Full Text] [Related]
20. One-step radiosynthesis and initial evaluation of a small molecule PET tracer for PD-L1 imaging.
Miao Y; Lv G; Chen Y; Qiu L; Xie M; Lin J
Bioorg Med Chem Lett; 2020 Dec; 30(24):127572. PubMed ID: 32979488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
